Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711201 | 0.86 | EPHX2 (0.49) | CYP2C9EPHX2NAMPTGPR119KDM4E | |
| SCHEMBL19652152 | 0.84 | NAMPT (0.48) | CYP2C9EPHX2NAMPTGPR119KDM4E | |
| SCHEMBL30711274 | 0.80 | GPR119 (0.65) | GPR119KDM4E | |
| SCHEMBL14413688 | 0.79 | CYP2C9 (0.52) | CYP2C9EPHX2NAMPTGPR119 | |
| SCHEMBL6232040 | 0.78 | KDM4E (0.38) | CYP2C9EPHX2KDM4E | |
| SCHEMBL14781405 | 0.78 | HSD11B1 (0.52) | KDM4E | |
| SCHEMBL7711264 | 0.78 | KDM4E (0.38) | CYP2C9EPHX2NAMPTPDE10AKDM4E | |
| SCHEMBL19658655 | 0.77 | MAPK11 (0.53) | CYP2C9QDPRPDE10AIKBKBMAPK11 | |
| SCHEMBL3178259 | 0.76 | GPR119 (0.59) | CYP2C9EPHX2NAMPTGPR119KDM4E | |
| SCHEMBL13107432 | 0.76 | GPR119 (0.59) | CYP2C9EPHX2NAMPTGPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CYP2C9 4277/4885EPHX2 2560/4885NAMPT 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.